Impact of treatment complexity on adherence and glycemic control: An analysis of oral antidiabetic agents

Journal of Clinical Outcomes Management

Volumn 17, Issue 6, 2010, Pages 20-30

  Pollack, Michael ^a   Chastek, Benjamin ^b   Williams, Setareh A ^a   Moran, Jane ^c  

^a ASTRAZENECA   (United Kingdom)

^b I3 Innovus ^*  (United States)

^c i3 Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROBABILITY; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 78649654674     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American Diabetes Association. Diabetes statistics. Accessed 29 Apr 2010 at www.diabetes.org/diabetes-stalistics.jsp.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta (GA): U.S. Department of Health and Human Services; 2008.
3. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615.
4. American Diabetes Association. Standards of medical care in diabetes in 2009. Diabetes Care 2009;32:S13-61.
5. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Pract 2007;13 (Suppl 1):5-68.
6. Gary TL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ 2003;29:488-501.
7. Boren SA, Fitzner KA, Panhalkar PS, Specter JE. Costs and benefits associated with diabetes education. Diabetes Educ 2009;35:72-96.
8. Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes. Diabetes Care 2002;25:1159-71.
9. Morris AD. Problems of multiple drug therapy in type 2 diabetes. Int J Clin Pract 2004;58(Suppl 142):45-8.
10. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40.
11. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;28:2868-79.
12. Cramer JA. A systemic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24.
13. Rubin RR. Adherence to pharmacological therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl 5A):27S-34S.
14. Willey CJ, Andrade SE, Cohen J, et al. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care 2006;12:435-40.
15. Berg JS, Dischler J, Wagner D, et al. Medication compliance: a health care problem. Ann Pharmacother 1993;27:S2-S19.
16. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third party managed care claims data. Clin Ther 2006;28:1712-25.
17. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient charactersitics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86.
18. Lawrence DB, Ragucci KR, Long LB, et al. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin a1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006;12:466-71.
19. RozenfekJ Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5.
20. Grant RW, Adams AS, Trinacty CM. Relationship between patient medication adherence and subsequent clinical inertia in type 2 dabetes glycemic management. Diabetes Care 2007;30:807-12.
21. U.S. Department of Health and Human Services. Health Information Privacy. Accessed 29 Apr 2010 at www.hhs.gov/ocr/privacy/index.html.
22. George J, Phun Y-T, Bailey MJ, et al. Development and validation of the medication regimen complexity index. Ann Pharmacother 2004;38:1369-76.
23. Martin S, Wolters PL, Calabrese SK, et al. The Antiretroviral Regimen Complexity Index. J Acquir Immune Syndr 2007;45:535-44.
24. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213-24.
25. Martin S, Elliot-DeSorbo DK, Woltens PL, et al. Patient, caregiver, and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect D J 2007;26:61-7. (Pubitemid 46045754)
26. Wickersham RM, Novak KK, editors. Drug facts and comparisons. St. Louis (MO): Wolters Kluwer Health; 2009.
27. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1701-73.
28. Blandford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Pharm 1999;5:47-51.
29. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8.
30. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61. (Pubitemid 34787476)
31. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62. (Pubitemid 28228203)
32. Charison ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
33. National Quality Forum. National Quality Forum endorses measures to improve medication safety and quality. Accessed 29 Apr 2010 at www.qualityforum.org/News-And-Resources/Press-Releases/2009/National-Quality- Forum-Endorses-Measures-to-Improve-Medication-Safety-and-Quality.aspx.